Abstract
Angiogenesis constitutes a major process in cancer progression, especially by promoting the growth of malignant cells and dissemination of metastases. The development of anti-angiogenic targeted therapies has made significant progress over the last decade. Since the discovery of bevacizumab, numerous therapies have been designed. Among them, small molecules that inhibit the tyrosine-kinase activity of pro-angiogenic receptors such as VEGFR, are the most studied today. Current research focuses on the development of new targeted-therapies, able to inhibit the activity of several receptors at the same time and with a greater affinity. This article reviews the data on anti-angiogenic targetedtherapies, from available molecules to drugs still in the process of development.
Résumé
L’angiogenèse constitue un processusmajeur de la progression tumorale, en particulier en favorisant la croissance des cellules malignes et leur dissémination sous forme de métastases. Depuis une dizaine d’années, le développement de thérapies ciblées antiangiogéniques connaît un grand engouement. Depuis la découverte du bevacizumab, de nombreuses autres thérapies ont été développées. Parmi elles, les inhibiteurs de l’activité tyrosinekinase des récepteurs proangiogéniques comme le VEGFR sont aujourd’hui les plus étudiés. La recherche actuelle est basée sur le développement de nouvelles thérapies ciblées pouvant inhiber l’activité de plusieurs récepteurs avec une grande affinité. Cette revue reprend les données actuelles sur les thérapies ciblées antiangiogéniques disponibles et en cours de développement.
Similar content being viewed by others
Références
Allegra CJ, Yothers G, O’Connell MJ, et al. (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29(1): 11–16
Anargyrou K, Dimopoulos MA, Sezer O, Terpos E (2008) Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 49(4): 677–689
Ansari J, Glaholm J, McMenemin R, et al. (2010) Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem 10(3): 225–235
Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19(5): 329–337
Cabebe E, Wakelee H (2006) Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 42(6): 387–398
Calvani N, Morelli F, Leo S, et al. (2011) Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol [Epub ahead of print]
Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8): 465–477
Chu E (2012) An update on the current and emerging targeted agents in meta-static colorectal cancer. Clin Colorectal Cancer 11(1): 1–13
D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9): 4082–4085
De Luca A, Normanno N (2010) Tivozanib, a pan-VEGFR tyrosine-kinase inhibitor for the potential treatment of solid tumors. IDrugs 13(9): 636–645
Deshpande HA, Gettinger S, Sosa JA (2010) Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid 4: 43–48
Dowlati A (2010) Hunting and trapping the vascular endothelial growth factor. J Clin Oncol 28(2): 185–187
Eskens FA, de Jonge MJ, Bhargava P, et al. (2011) Biological and clinical activity of tivozanib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine-kinases, in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Clin Cancer Res 17(22): 7156–7163
Figueiras RG, Padhani AR, Goh VJ, et al. (2011) Novel oncologic drugs: what they do and how they affect images. Radiographics 31(7): 2059–2091
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21): 1182–1186
Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19(0): 331–358
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16): 15–18
Fruehauf JP, Lutzky J, McDermott DF, et al. (2011) Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, 3, in patients with metastatic melanoma. Clin Cancer Res 17(23): 7462–7469
Garcia JA, Roberts LR (2012) Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. J Hepatol 56(2): 486–487
Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2(12): 733–740
Gild ML, Bullock M, Robinson BG, Clifton-Bligh R (2011) Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 7(10): 617–624
Glen H, Mason S, Patel H, et al. (2011) E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 11: 309
Grünwald V, Seidel C, Fenner M, et al. (2011) Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 105: 1635–1639
Hahn O, Stadler W (2006) Sorafenib. Curr Opin Oncol 18(6): 615–621
Heldin CH, Westermark B (1990) Signal transduction by the receptors for platelet-derived growth factor. J Cell Sci 96(Pt 2): 193–196
Herbst RS, Hong D, Chap L, et al. (2009) Safety, pharmacokinetics, and antitumor activity of AMG-386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21): 3557–3565
Ho TH, Jonasch E (2011) Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol 7(11): 1247–1253
Hwang C, Heath EI (2010) Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 3: 26
Ishikawa T, Kanda T, Kosugi S, et al. (2011) Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors. Gan To Kagaku Ryoho 38(6): 916–921
Khoury CC, Ziyadeh FN (2011) Angiogenic factors. Contrib Nephrol 170: 83–92. Epub 2011 Jun 9
Ledermann JA, Hackshaw A, Kaye S, et al. (2011) Randomized phase II placebocontrolled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29(28): 3798–3804
Leighl NB, Raez LE, Besse B, et al. (2010) A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5(7): 1054–1059
Lindsay CR, MacPherson IR, Cassidy J (2009) Current status of cediranib: the rapid development of a novel antiangiogenic therapy. Future Oncol 5(4): 421–432
Melichar B, Studentová H, Zezulová M (2011) Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors. J BUON 16(2): 203–209
Merino M, Pinto A, González R, Espinosa E (2011) Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer 47(12): 1846–1851
Miller MT, Strömland K (1999) Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60(5): 306–321
Monk BJ, Willmott LJ, Sumner DA (2010) Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 116(2): 181–186
Moserle L, Amadori A, Indraccolo S (2009) The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med 9(8): 935–941
Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24(35): 5601–5608
Oberstein PE, Saif MW (2011) Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP 12(4): 358–361
Qi WX, Tang LN, He AN, et al. (2011) The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 189(6): 437–443
Ranieri G, Patruno R, Ruggieri E, et al. (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13(16): 1845–1857
Razumilava N, Gores GJ (2011) Sorafenib for HCC: a pragmatic perspective. Oncology (Williston Park) 25(3): 300, 302
Reinhold HS, van den Berg-Blok A (1984) Factors influencing the neovascularization of experimental tumours. Biorheology 21(4): 493–501
Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5): 361–369
Rini BI, Escudier B, Tomczak P, et al. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807): 1931–1939
Risau W (1998) Angiogenesis is coming of age. Circ Res 82(8): 926–928
Risau W (1998) Development and differentiation of endothelium. Kidney Int Suppl 67: S3–S6
Robson EJ, Ghatage P (2011) AMG-386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 20(2): 297–304
Shahshahan MA, Beckley MN, Jazirehi AR (2011) Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. Am J Cancer Res 1(7): 913–924
Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11): 1779–1802
Sloan B, Scheinfeld NS (2008) Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 9(12): 1324–1335
Sobrero AF, Bruzzi P (2011) Vatalanib in advanced colorectal cancer: two studies with identical results. J Clin Oncol 29(15): 1938–1940
Spratlin JL, Cohen RB, Eadens M, et al. (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5): 780–787
Spratlin JL, Mulder KE, Mackey JR (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 6(7): 1085–1094
Stewart MW (2011) Aflibercept (VEGFTRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 10(6): 497–508
Stoelting S, Trefzer T, Kisro J, et al. (2008) Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 22(6): 831–836
Tageja N (2011) Lenalidomide: current understanding of mechanistic properties. Anticancer Agents Med Chem 11(3): 315–326
Takami HE (2011) Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. Endocr J 58(3): 151–153
Uraizee I, Cheng S, Moslehi J (2011) Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med 365(17): 1649–1650
Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9(17): 6316–6325
Wilhelm SM, Dumas J, Adnane L, et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1): 245–255
Zustovich F, Lombardi G, Nicoletto O, Pastorelli D (2011) Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol [Epub ahead of print]
Référence électronique
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Watson, S., de La Motte Rouge, T. Antiangiogéniques: les anciens et les nouveaux. Oncologie 14, 216–225 (2012). https://doi.org/10.1007/s10269-012-2142-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-012-2142-4